Integral Diagnostics Limited (ASX:IDX)
Australia · Delayed Price · Currency is AUD | Market Cap | 867.90M -14.3% |
| Revenue (ttm) | 788.62M +25.7% |
| Net Income | 21.93M +715.7% |
| EPS | 0.06 +561.4% |
| Shares Out | 372.49M |
| PE Ratio | 40.17 |
| Forward PE | 17.39 |
| Dividend | 0.09 (3.99%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 2,034,626 |
| Open | 2.330 |
| Previous Close | 2.330 |
| Day's Range | 2.295 - 2.330 |
| 52-Week Range | 1.905 - 3.040 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 3.01 (+29.19%) |
| Earnings Date | Aug 25, 2026 |
About Integral Diagnostics
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia. [Read more]
Financial Performance
In fiscal year 2026, Integral Diagnostics's revenue was 788.62 million, an increase of 25.73% compared to the previous year's 627.22 million. Earnings were 21.93 million, an increase of 715.66%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for IDX stock is "Buy." The 12-month stock price target is $3.01, which is an increase of 29.19% from the latest price.
News
Integral Diagnostics Earnings Call Transcript: H2 2026
FY 2026 saw revenue rise 25.6% to AUD 788.7 million and operating EBITDA margin improve to 20.9%, driven by organic growth, acquisitions, and strong demand. Strategic priorities for FY 2027 include margin expansion, disciplined capital management, and leveraging industry tailwinds such as MRI deregulation.
Integral Diagnostics Slides: H2 2026
Integral Diagnostics has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 24, 2026.
Integral Diagnostics Annual report: H2 2026
Integral Diagnostics has published its H2 2026 annual report on August 24, 2026.
Integral Diagnostics Earnings release: H2 2026
Integral Diagnostics released its H2 2026 earnings on August 24, 2026, summarizing the period's financial results.
Integral Diagnostics Earnings Call Transcript: H1 2026
Revenue grew 55.6% to AUD 393.5 million, with EBITDA margin up 230 bps to 20.6% and strong synergy realization from the Capitol merger. Ongoing investments in AI, teleradiology, and new sites support further growth, while integration costs are trending down.
Integral Diagnostics Quarterly report: H1 2026
Integral Diagnostics has published its H1 2026 quarterly earnings report on February 23, 2026.
Integral Diagnostics Slides: H1 2026
Integral Diagnostics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 23, 2026.
Integral Diagnostics Earnings release: H1 2026
Integral Diagnostics released its H1 2026 earnings on February 23, 2026, summarizing the period's financial results.
Integral Diagnostics Transcript: AGM 2025
The meeting highlighted strong revenue and margin growth, successful Capital Health integration, and robust sustainability and governance initiatives. Shareholders approved new directors, CEO incentives, and a special resolution, while Q&A addressed radiologist retention, AI, and future growth.
Integral Diagnostics Slides: FY 2025
Integral Diagnostics has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 30, 2025.